



DNDi @ ASTMH 2016

Drugs for Neglected Diseases *initiative* (DNDi)
presentations at the American Society of Tropical Medicine
and Hygiene (ASTMH), 65th Annual Meeting



NOVEMBER 13-17, 2016

Atlanta Marriott Marquis and Hilton Atlanta
Atlanta, Georgia USA



DNDi @ ASTMH 2016

Drugs for Neglected Diseases *initiative* (DNDi)
American Society of Tropical Medicine and Hygiene (ASTMH)

NOVEMBER 13-17, 2016 • ATLANTA

<http://www.dndi.org/astmh2016/>

Monday, November 14, 2016

Oral Presentation (Sponsored by DNDi)

Excess mortality associated with high Loa loa microfilaremia in the East Region of Cameroon: a retrospective cohort study

- **Session title:** Session 2 - Filariasis: Epidemiology and Control I
- **Time:** 8:15 - 8:30 AM
- **Authors:** Cédric B. Chesnais¹, Innocent Takougang², Marius Paguele³, Michel Boussinesq¹, Sébastien D. Pion¹

Tuesday, November 15, 2016

DNDi Symposium – Session #74

Recent advances in the development of new treatments for chronic Chagas disease

- **Time:** 10:15 - 12:00 PM
- **Location:** Marriott - Atrium B
- **Chair:** Sergio Sosa Estani (Director, Fatała Chaben Institute, Argentina)
- **Co-chair:** Isabela Ribeiro (DNDi, Geneva)
- **Speaker 1:** Review of recent preclinical information and pharmacokinetic-pharmacodynamic data in Chagas disease. Isabela Ribeiro, Head of Chagas Clinical Program, DNDi
- **Speaker 2:** Biological markers of therapeutic response in Chagas disease – new developments. Igor Almeida, University of Texas El Paso, El Paso, United States
- **Speaker 3:** New treatment regimens of benznidazole – preclinical results and overview of planned studies. Joaquim Gascon Brustenga, IS Global Barcelona Institute for Global Health, Barcelona, Spain
- **Speaker 4:** Nifurtimox for Chagas disease – recent clinical studies and perspectives. Dr Jaime Altcheh, Hospital de Niños, Ricardo Gutierrez, Buenos Aires, Argentina



Visit us at the DNDi Booth! #418

Poster (1119)

Identification of new macrofilaricidal compounds for treatment of onchocerciasis

- **Session title:** 79 - Poster Session B: Presentations and Light Lunch
- **Time:** 12:00 - 1:45 PM
- **Authors:** Marc P. Hübner⁴, Achim Hoerauf⁴, Simon Townson⁵, Suzanne Gokool⁵, Coralie Martin⁶, Agnieszka Chojnowski⁷, Tamara Kreiss⁷, Monika Prorok⁷, John Siekierka⁷, Jerome Zeldis⁸, Stacie Canan⁹, Vikram Khetani⁸, Ivan Scandal¹⁰, Natalie A. Hawryluk⁹

Poster (1100)

Impact of ivermectin mass treatment on the burden of onchocercal skin and eye disease: detailed model predictions up to 2025

- **Session title:** 79 - Poster Session B: Presentations and Light Lunch
- **Time:** 12:00 - 1:45 PM
- **Authors:** Natalie V. S. Vinkeles Melchers¹¹, Luc E. Coffeng¹¹, Michele E. Murdoch¹², Belén Pedrique¹³, Roel Bakker¹¹, Gladys A. Ozoh¹⁴, Sake J. de Vlas¹¹, Wilma A. Stolk¹¹

DNDi Symposium – Session #102

Approaches, advances and needs for the elimination of human African trypanosomiasis (HAT)

- **Time:** 4:00 - 5:45 PM
- **Location:** Marriott - Room A706/A707
- **Chair:** Gerardo Priotto, Department of Control of Neglected Tropical Diseases, WHO
- **Co-chair:** Crispin Lumbala, Programme national de Lutte contre la THA, Democratic Republic of Congo
- **Speaker 1:** How can we achieve HAT elimination by 2020?
Gerardo Priotto, Medical Officer, Department of Control of Neglected Tropical Diseases, World Health Organization (WHO)
- **Speaker 2:** Diagnosis of HAT: new tools in a changing context.
Veerle Lejon, Institut de Recherche pour le Développement
- **Speaker 3:** Clinical development of new oral treatments for HAT.
Antoine Tarral, DNDi
- **Speaker 4:** Human African Trypanosomiasis – A bio-centric hit to lead approach to identify new lead series.
Jan Jiricek, NITD HAT Project Team Leader, Novartis



Wednesday, November 16, 2016

Poster (131)

LB-5386 - Re-analysis of a sequential three-arm randomized trial of AmBisome in combination with sodium stibogluconate or miltefosine, and miltefosine monotherapy, for African visceral leishmaniasis

- **Session title:** Poster Session C: Presentations and Light Lunch
 - **Time:** 12:00 – 1:45 PM
 - **Authors:** Neal D. Alexander¹⁵, Annabel Allison¹⁶, Tansy Edwards¹⁵, Raymond Omollo¹⁷, Dominic Magirr¹⁸, Fabiana Alves¹⁹, Ahmed Musa²⁰, Monique Wasunna¹⁷
-

Poster (131) Non-DNDi

Sociocultural factors and access to treatment for Chagas disease in Los Angeles

- **Session title:** Poster Session C
 - **Time:** 12:00 - 1:45 pm
 - **Authors:** Colin J. Forsyth^{21,22}, Salvador Hernandez²¹, Mario Felipe Roman Cadena²¹, Juana Maribel Nieto Rivas²¹, Grecia Marquez Lizama²¹, Carmen Aida Flores²¹, Juan Carlos Sequeira Gross²¹, Sheba K. Meymandi²¹.
-

DNDi Symposium – Session #142

Bridging the gap between patients and access to Chagas treatment: lessons learnt from scaling-up models in Latin America and the US (with the Chagas Coalition)

- **Time:** 1:45 - 3:30 PM
 - **Location:** Marriott – Atrium B
 - **Chair:** Peter Hotez, George Washington University, Texas
 - **Speaker 1:** Why should treating Chagas be a priority? What are the access barriers to overcome?
Rafael Vilasanjuan, Barcelona Institute for Global Health
 - **Speaker 2:** Chagas disease, a Global health problem in the US: Gaps and challenges.
Sheba Meymandi, Olive View, University of California, Los Angeles, Medical Center
 - **Speaker 3:** Scaling up access to treatment: Lessons learned in endemic and non-endemic countries.
Carolina Batista, DNDi Rio
 - **Speaker 4:** Scaling up access in Bolivia, the country with the highest prevalence.
Joaquim Gascon Brustenga, Barcelona Institute for Global Health
-

¹⁵ London School of Hygiene and Tropical Medicine, London, United Kingdom; ¹⁶ University of Sheffield, Sheffield, United Kingdom; ¹⁷ DNDi, Nairobi, Kenya; ¹⁸ Medical University of Vienna, Vienna, Austria; ¹⁹ DNDi, Geneva, Switzerland; ²⁰ Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan; ²¹ Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, Los Angeles, CA, USA; ²² DNDi
